Use the NIA Research Resources database to find NIA-supported scientific resources, datasets, informatics resources, and more. Search by keyword, resource type, or NIA Division or IRP.
Clinical Research Resources
Alzheimer's and Dementia Outreach, Recruitment, and Engagement (ADORE) Resources
This NIA web-based searchable collection of tools and resources supports the recruitment and retention of participants into clinical trials and studies on Alzheimer’s disease and related dementias. ADORE resources include recruitment plans, communication materials, toolkits and guides, videos, and related research articles. Users can browse by category, search by keyword, or explore by tags.
Alzheimer's Preclinical Efficiency Database (AlzPED)
AlzPED is a publicly available, searchable, data resource that aims to increase the transparency, reproducibility and translatability of preclinical efficacy studies of candidate therapeutics for Alzheimer’s disease. AlzPED is designed as a knowledge platform for the dissemination of data and analysis to scientists, from academic centers, industry, disease-focused foundations, in a manner that promotes efficiency, transparency, reproducibility and accuracy of research aimed at preclinical therapy development for AD. AlzPED provides quick access and visibility to integrated preclinical efficacy data from published and unpublished studies. Visit the AlzPED website.
International Alzheimer's and Related Dementias Research Portfolio (IADRP)
A new database created to capture the full spectrum of current Alzheimer’s disease research investments and resources—both in the U.S. and internationally—is now publicly available. The International Alzheimer's and Related Dementias Research Portfolio (IADRP), developed by the NIA, in collaboration with the Alzheimer’s Association, will enable public and private funders of Alzheimer’s research to coordinate research planning, leverage resources, avoid duplication of funding efforts and identify new opportunities in promising areas of growth. The newly developed resource, currently hosted and maintained by NIA, helps to track and implement research goals of the National Plan to Address Alzheimer’s Disease (NAPA).
National Alzheimer's Coordinating Center (NACC)
Funded by NIA, the National Alzheimer's Coordinating Center (NACC) has developed and maintains a large relational database of standardized clinical and neuropathological research data. NACC provides a valuable resource for both exploratory and explanatory Alzheimer's disease research. NACC data are freely available to all researchers.
Resources for Enhancing Alzheimer's Caregiver Health (REACH)
The REACH study was a multisite caregiver intervention study that compared a variety of interventions for dementia caregivers to control conditions. The study was a landmark in its large sample size, use of multiple sites, and inclusion of large numbers of White, Hispanic, and African American caregivers.
To facilitate aging research on cells in culture, the NIA provides support for the NIA Aging Cell Repository, located at the Coriell Institute for Medical Research in Camden, NJ. Included are skin fibroblast cultures from individuals with premature aging syndromes, including Werner and Hutchinson-Guilford (progeria), cultures from clinically documented and at-risk individuals from families exhibiting familial Alzheimer's disease, differentiated cell lines, and cell lines from animals. The repository also has DNA from many of the cell lines, available individually or in panels such as the Primate DNA panel, Aging Syndrome DNA panel, Characterized Alzheimer's disease mutation DNA panel, Early and Late Onset Alzheimer's disease DNA panels, and Aged Sib Pairs DNA panel.
IND Toxicology Service
The NIA sponsors the Investigational New Drug (IND) Toxicology program to identify compounds for use in symptoms of Alzheimer’s and other aging-related diseases. The program provides toxicology services to academic and small business investigators who believe they have promising compounds for the treatment or prevention of Alzheimer’s disease, but lack the resources to perform the required toxicology studies. NIA will give investigators access to toxicological evaluations required by the Food and Drug Administration (FDA) as part of requests for IND designations for clinical studies. NIA hopes this preclinical drug-development program will expand the potential range of drug therapies for Alzheimer’s and other aging-related diseases by making these resources available to a larger and more diverse group of investigators.
SRI International provides services for this program in four general categories:
- analytical chemistry,
- pharmacokinetics and bioavailability,
- preliminary toxicity screens, and
- IND-directed toxicology studies, including safety pharmacology.
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)
National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD). This NIH-funded repository provides resources that help researchers identify the genes that contribute to Alzheimer’s and other types of dementia. NCRAD collects and maintains biological specimens and associated data on study volunteers from a variety of sources, primarily people enrolled at ADCs, as well as those in the Alzheimer’s Disease Neuroimaging Initiative, the Alzheimer’s Disease Genetics Consortium, and other studies. NCRAD also houses DNA samples and data from more than 900 families with multiple members affected by Alzheimer’s. Since it was funded 22 years ago, more than 150,000 biological samples have been requested and sent to more than 120 investigators and research centers across the world.
NIA Genetics of Alzheimer's Disease Data Storage Site (NIAGADS)
NIAGADS organizes, stores, and shares genetic, genomic, and phenotypic data, including clinical and neuropathology data, from NIH-funded genetic studies in a secure environment. NIAGADS currently hosts 76 high-quality human genetics datasets in addition to Alzheimer’s Disease Sequencing Project (ADSP) data, corresponding to 55,241 participants, and has a genomics database for cross-referencing and visualizing known genomic variants and annotations with Alzheimer’s Disease (AD) genetic analysis findings.
The ADSP provides genetic data from large numbers of genetically informative, multi-ethnic, phenotypically well-characterized families having multiple individuals affected with AD, and includes Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD) cases and controls. NIAGADS is the ADSP Data Coordinating Center that supports ADSP data production, management, and sharing. A partial list of NIAGADS’s many responsibilities includes scheduling, preparing, and maintaining public data releases. NIAGADS also maintains the ADSP website and facilitates community access to ADSP data.
NIAGADS was charged with developing a fully featured data-sharing service for ADSP using cloud technology that was compliant with both Health Insurance Portability & Accountability Act (HIPAA) and the Federal Information Security Management Act of 2002 (FISMA). The NIAGADS Data Sharing Service (DSS) was launched in July 2018 and facilitates the deposition and sharing of genomic data from the ADSP and other NIA-funded AD/ADRD genomic studies with approved users in the research community. NIAGADS provides qualified investigators with several different types of data from genetic/genomic studies, including high-density genotyping and sequencing data, extensive phenotype data, and summary statistics from published genetic studies.
The DSS currently hosts 16,905 whole genomes and 20,503 whole exomes from the ADSP. Later in 2022 there will be a total of ~37,000 ADSP whole genomes available through NIAGADS DSS.